Drooling in adults signals a medical problem. Unlike infants, adults should have the neuromuscular control to manage saliva. When that control fails, whether from Parkinson’s disease, stroke, cerebral palsy, or ALS, sialorrhea results. The constant wetness damages skin, soils clothing, and isolates patients socially. Botox injected into the salivary glands reduces saliva production at the source, providing relief when anticholinergic medications fail or cause intolerable side effects.
Salivary Gland Anatomy
Three paired major salivary glands produce most of our saliva:
Parotid glands: The largest, located in front of and below each ear. They produce watery (serous) saliva, primarily during eating. Each parotid wraps around the mandible and can be palpated by pressing in front of the earlobe.
Submandibular glands: Located beneath the jaw, these produce mixed serous and mucous saliva. They contribute significantly to baseline saliva production and are often the primary treatment target.
Sublingual glands: The smallest, located under the tongue. They produce primarily mucous saliva and are less commonly targeted for sialorrhea treatment.
| Gland | Location | Saliva Type | Treatment Priority |
|---|---|---|---|
| Parotid | Pre-auricular | Serous (watery) | Secondary target |
| Submandibular | Submental | Mixed | Primary target |
| Sublingual | Sublingual | Mucous | Rarely treated |
The submandibular glands produce the largest volume of unstimulated saliva, making them the primary target for sialorrhea treatment. The parotids are added when submandibular treatment alone provides inadequate relief.
Ultrasound-Guided Injection
Unlike facial Botox, which targets visible or palpable muscles, salivary gland injection benefits from imaging guidance. The glands lie deep to skin and other structures; confident identification without imaging is difficult.
Ultrasound guidance:
- Visualizes the gland in real time
- Confirms needle placement within gland tissue
- Avoids adjacent structures (facial nerve branches, blood vessels)
- Improves consistency of results
Technique: The ultrasound probe is placed over the gland location. Once the gland is identified on screen, the needle advances under direct visualization. Botox is injected when the needle tip is confirmed within gland parenchyma.
Without guidance: Some experienced practitioners inject based on anatomical landmarks alone. The parotid is relatively easy to locate by palpation; the submandibular less so. Unguided injection works but carries higher risk of missing the target or affecting nearby structures.
The facial nerve traverses the parotid gland. Careless injection can cause temporary facial weakness. Ultrasound guidance helps avoid this complication by visualizing needle placement relative to nerve anatomy.
Dosing Guidelines
The FDA approved Botox for sialorrhea in 2018, providing established dosing:
Approved dose: 100 units total, distributed as:
- 30 units per parotid gland (60 units total)
- 20 units per submandibular gland (40 units total)
Some practitioners adjust based on clinical response:
- Submandibular-only treatment (40-60 units total) for mild cases
- Higher doses (up to 150 units total) for severe or refractory cases
Injection points: 2-3 injections per gland distribute the toxin throughout the tissue.
Treatment interval: Every 12-16 weeks, adjusted to individual response. Some patients maintain adequate saliva control for up to 20 weeks; others need retreatment at 10-12 weeks.
Neurological Populations
Most sialorrhea patients have underlying neurological conditions. The treatment must account for their specific circumstances:
Parkinson’s disease: The most common indication. Impaired swallowing (dysphagia) and reduced spontaneous swallowing cause saliva pooling. Botox helps but does not address the underlying swallowing dysfunction. Patients may still need swallowing therapy.
Stroke: Unilateral weakness affects swallowing coordination. Sialorrhea severity often correlates with stroke severity. Recovery potential affects treatment decisions; some patients improve spontaneously and may not need indefinite treatment.
ALS (amyotrophic lateral sclerosis): Progressive weakness affects swallowing early in many patients. Sialorrhea significantly impacts quality of life. Treatment provides meaningful relief during the disease course.
Cerebral palsy: Lifelong drooling affects social integration and skin health. Treatment may begin in childhood and continue indefinitely. The FDA approval includes pediatric dosing (children 2 years and older).
Head and neck cancer survivors: Radiation damage can paradoxically cause either dry mouth or altered saliva consistency. Some patients produce thick, difficult-to-manage saliva that Botox can help reduce.
Dry Mouth Concerns
Reducing saliva carries risk: xerostomia (dry mouth) can cause:
- Discomfort and difficulty swallowing
- Dental decay from reduced saliva’s protective effects
- Altered taste
- Increased oral infections
The goal is balanced reduction, enough to control drooling without eliminating saliva entirely.
Dose titration helps achieve balance. Starting with lower doses and increasing if needed allows finding the minimum effective dose for each patient.
Patient selection matters. Patients with borderline saliva production, those on other anticholinergic medications, or those with existing dry mouth may not be good candidates.
Reversibility provides safety margin. If dry mouth occurs, it resolves as the Botox wears off over 3-4 months. Patients are not permanently harmed by overtreatment.
Monitoring includes asking about dry mouth symptoms at each treatment visit. Dose reduction or extended intervals address emerging xerostomia.
Important: Sialorrhea often indicates an underlying neurological condition requiring comprehensive medical management. This article provides general information only and is not a substitute for professional medical advice. Consult a neurologist, otolaryngologist, or the physician managing your underlying condition before pursuing this treatment.
Sources:
- FDA approval and dosing: Allergan prescribing information for onabotulinumtoxinA, sialorrhea indication
- Ultrasound technique: American Journal of Otolaryngology, “Ultrasound-Guided Botulinum Toxin Injection for Sialorrhea”
- Neurological populations: Movement Disorders, “Botulinum Toxin for Sialorrhea in Parkinson’s Disease”
- Xerostomia management: Oral Surgery, Oral Medicine, Oral Pathology, “Complications of Salivary Gland Botulinum Toxin”